RU2006108557A - Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения) - Google Patents
Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения) Download PDFInfo
- Publication number
- RU2006108557A RU2006108557A RU2006108557/15A RU2006108557A RU2006108557A RU 2006108557 A RU2006108557 A RU 2006108557A RU 2006108557/15 A RU2006108557/15 A RU 2006108557/15A RU 2006108557 A RU2006108557 A RU 2006108557A RU 2006108557 A RU2006108557 A RU 2006108557A
- Authority
- RU
- Russia
- Prior art keywords
- parathyroid hormone
- alkylidene
- vitamin
- treatments
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
Claims (7)
1. Фармацевтическая композиция, включающая в себя соединение 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамина D3 и паратиреоидный гормон или его активный фрагмент или вариант.
2. Композиция по п.1, в которой паратиреоидный гормон представляет собой рекомбинантный паратиреоидный гормон человека.
3. Композиция по п.1, в которой паратиреоидный гормон представляет собой рекомбинантный паратиреоидный гормон человека 1-34.
4. Способ лечения сенильного остеопороза, постклимактерического остеопороза, перелома кости, пересадки кости, рака молочной железы, рака простаты, ожирения, остеопении, мужского остеопороза, хрупкости, повреждения мышц или саркопении у пациента, включающий в себя введение пациенту, нуждающемуся в таком лечении, терапевтически эффективного количества 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамина D3 и паратиреоидного гормона или его активного фрагмента или варианта.
5. Способ по п.4, согласно которому 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамин D3 и паратиреоидный гормон или его активный фрагмент или вариант вводят по существу одновременно.
6. Способ по п.4, согласно которому лечат постклимактерический остеопороз.
7. Способ по п.4, согласно которому лечат перелом кости.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50450303P | 2003-09-19 | 2003-09-19 | |
US60/504,503 | 2003-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006108557A true RU2006108557A (ru) | 2007-09-27 |
Family
ID=34375509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006108557/15A RU2006108557A (ru) | 2003-09-19 | 2004-09-06 | Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения) |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050065088A1 (ru) |
EP (1) | EP1667689A1 (ru) |
JP (1) | JP2007505883A (ru) |
KR (1) | KR20060058133A (ru) |
CN (1) | CN1852716A (ru) |
AU (1) | AU2004273660B2 (ru) |
BR (1) | BRPI0414518A (ru) |
CA (1) | CA2539357A1 (ru) |
IL (1) | IL174144A0 (ru) |
MX (1) | MXPA06003064A (ru) |
NO (1) | NO20061236L (ru) |
NZ (1) | NZ545803A (ru) |
RU (1) | RU2006108557A (ru) |
TW (1) | TW200511999A (ru) |
WO (1) | WO2005027915A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122533B2 (en) * | 1999-11-29 | 2006-10-17 | The United States Of America As Represented By The Department Of Health And Human Services | Cosalane compounds and methods for their use |
EP1694333A2 (en) * | 2003-11-25 | 2006-08-30 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin d compounds |
MXPA06005887A (es) * | 2003-11-25 | 2006-06-27 | Wisconsin Alumni Res Found | Analogos de vitamina d para la prevencion y el tratamiento de la obesidad. |
AU2006213727B2 (en) * | 2005-02-11 | 2011-08-18 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2 |
MX2007009725A (es) * | 2005-02-11 | 2007-09-26 | Wisconsin Alumni Res Found | 2-metilen-19-nor-(20s-24epi)-1a, 25-dihidroxivitamina-d2. |
US7235680B2 (en) * | 2005-03-29 | 2007-06-26 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone |
WO2011119610A2 (en) | 2010-03-23 | 2011-09-29 | Wisconsin Alumni Research Foundation | (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3 |
US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
US20110237557A1 (en) * | 2010-03-23 | 2011-09-29 | Deluca Hector F | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3 |
WO2015050160A1 (ja) * | 2013-10-03 | 2015-04-09 | 国立大学法人大阪大学 | 副甲状腺ホルモンまたはその誘導体を有効成分とする筋の老化防止用医薬組成物 |
JP6566520B2 (ja) * | 2013-10-29 | 2019-08-28 | 国立大学法人 熊本大学 | 筋疾患の治療または予防のための医薬組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
DE69400495T2 (de) * | 1993-04-05 | 1997-04-30 | Wisconsin Alumni Res Found | 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle |
US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
AR033639A1 (es) * | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
SI1059933T1 (en) * | 1998-08-19 | 2003-04-30 | Eli Lilly & Company | Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture |
-
2004
- 2004-09-06 CN CNA2004800268486A patent/CN1852716A/zh active Pending
- 2004-09-06 CA CA002539357A patent/CA2539357A1/en not_active Abandoned
- 2004-09-06 KR KR1020067005457A patent/KR20060058133A/ko not_active Application Discontinuation
- 2004-09-06 WO PCT/IB2004/002902 patent/WO2005027915A1/en active Application Filing
- 2004-09-06 EP EP04769301A patent/EP1667689A1/en not_active Withdrawn
- 2004-09-06 JP JP2006526715A patent/JP2007505883A/ja active Pending
- 2004-09-06 AU AU2004273660A patent/AU2004273660B2/en not_active Expired - Fee Related
- 2004-09-06 MX MXPA06003064A patent/MXPA06003064A/es unknown
- 2004-09-06 RU RU2006108557/15A patent/RU2006108557A/ru not_active Application Discontinuation
- 2004-09-06 BR BRPI0414518-6A patent/BRPI0414518A/pt not_active IP Right Cessation
- 2004-09-06 NZ NZ545803A patent/NZ545803A/en unknown
- 2004-09-16 US US10/946,585 patent/US20050065088A1/en not_active Abandoned
- 2004-09-17 TW TW093128228A patent/TW200511999A/zh unknown
-
2006
- 2006-03-06 IL IL174144A patent/IL174144A0/en unknown
- 2006-03-17 NO NO20061236A patent/NO20061236L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL174144A0 (en) | 2006-08-01 |
CN1852716A (zh) | 2006-10-25 |
EP1667689A1 (en) | 2006-06-14 |
AU2004273660A1 (en) | 2005-03-31 |
NO20061236L (no) | 2006-06-15 |
BRPI0414518A (pt) | 2006-11-07 |
MXPA06003064A (es) | 2006-05-31 |
CA2539357A1 (en) | 2005-03-31 |
JP2007505883A (ja) | 2007-03-15 |
KR20060058133A (ko) | 2006-05-29 |
WO2005027915A1 (en) | 2005-03-31 |
AU2004273660B2 (en) | 2010-08-19 |
TW200511999A (en) | 2005-04-01 |
US20050065088A1 (en) | 2005-03-24 |
NZ545803A (en) | 2008-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
EA200501023A1 (ru) | Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида | |
RU2001128504A (ru) | Композиции для стимулирования роста | |
RU2006108557A (ru) | Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения) | |
IL214373A0 (en) | Use of adipose tissue-derived cells in the preparation of a composition for the treatment of cardiovascular diseases | |
HUP0400607A3 (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
RU2004107899A (ru) | 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона | |
WO2005072277A3 (en) | Amidated parathyroid hormone fragments and uses thereof | |
RU2003136733A (ru) | Пероральное введение паратиреоидного гормона и кальцитонина | |
EP1348466A3 (en) | Method for treating pain with adenosine-tetraphosphates | |
RU2006107652A (ru) | Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d агониста/антагониста эстрогенов | |
JP2007505883A5 (ru) | ||
BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
JP2007505881A5 (ru) | ||
RU2007117492A (ru) | Применение органических соединений | |
JP2003528919A5 (ru) | ||
RU2002129355A (ru) | Применение фульвестранта при лечении резистентного рака молочной железы | |
WO1999056666A8 (en) | The treatment of sexual dysfunction in certain patient groups | |
RU2005102923A (ru) | Средство от диабета | |
WO2005120540A3 (en) | Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction | |
WO2004112565A3 (en) | Diagnosis and treatment of liver, pulmonary and cardiac fibrosis | |
CN1085550C (zh) | 风湿药及其制造方法 | |
RU2006108528A (ru) | Производные 2-алкилиден-19-нор-витамина d для лечения остеопении или мужского остеопороза | |
EA200600757A1 (ru) | Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080311 |